LP
CMPX icon

LMR Partners’s Compass Therapeutics CMPX Stock Holding History

LMR Partners’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-80,692
Closed -$257K – 953
2023
Q2 		$257K Sell
80,692
-65,481
-45% -$206K ﹤0.01% 565
2023
Q1 		$478K Buy
146,173
+21,234
+17% +$83.4K 0.01% 735
2022
Q4 		$628K Buy
124,939
+24,939
+25% +$99.5K 0.01% 815
2022
Q3 		$228K Hold
100,000
– – ﹤0.01% 996
2022
Q2 		$265K Hold
100,000
– – ﹤0.01% 1024
2022
Q1 		$137K Hold
100,000
– – ﹤0.01% 1169
2021
Q4 		$317K Buy
+100,000
New +$332K ﹤0.01% 1008

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

LMR Partners's CMPX Position: Q3 2023 in Review

LMR Partners sold out of Compass Therapeutics (CMPX) in Q3 2023, closing a stake of 80,692 shares — an estimated $257K sold.

LMR Partners first reported a position in CMPX in Q4 2021 and held it in 7 quarters. The position peaked at $628K in Q4 2022. 76 funds tracked by Wall St. Rank hold CMPX as of Q3 2023.

  • LMR Partners reported no remaining Compass Therapeutics position as of Q3 2023 after selling out during the quarter.
  • LMR Partners sold 80,692 Compass Therapeutics shares in Q3 2023, an estimated $257K.
  • LMR Partners first reported a position in Compass Therapeutics in Q4 2021 and held it in 7 quarters.
  • LMR Partners's Compass Therapeutics position peaked at $628K in Q4 2022.
  • 76 funds tracked by Wall St. Rank held Compass Therapeutics as of Q3 2023.

Based on LMR Partners's 13F filing for Q3 2023, filed 14 Nov 2023.